Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Clinical-development physician in a company with a CMC site change mid-review has one working extract — complete-response-letter deficiency list — after a payer demanding RWE the protocol cannot generate. If complete-response-letter deficiency list cannot support to drop a secondary, the only defensible Pharma & Life Sciences output is hold.

DECISION Clinical-development physician in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. Clinical-development physician can defend Proceed under protocol from complete-response-letter deficiency list after a payer demanding RWE the protocol cannot generate in a Pharma & Life Sciences challenge. 2. Clinical-development physician cannot defend Proceed under protocol from complete-response-letter deficiency list; Pause the pathway is what the extract actually supports after a payer demanding RWE the protocol cannot generate. 3. A payer demanding RWE the protocol cannot generate never reached the population in complete-response-letter deficiency list — reopen intake, do not close to drop a secondary. 4. Two facts in complete-response-letter deficiency list after a payer demanding RWE the protocol cannot generate conflict for clinical-development physician; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a payer demanding RWE the protocol cannot generate. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read complete-response-letter deficiency list against a payer demanding RWE the protocol cannot generate and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (complete-response-letter deficiency list after a payer demanding RWE the protocol cannot generate). The follow-on FDA Response and Labeling action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in complete-response-letter deficiency list, then the action for clinical-development physician - Hypothesis scorecard against complete-response-letter deficiency list: supported / rejected / untestable - Missing page in complete-response-letter deficiency list after a payer demanding RWE the protocol cannot generate, if any - Regulatory or exam hook FDA Response and Labeling would cite